1146 documents

Read All
20:56 , Jul 15, 2019 |  BC Extra  |  Company News

July 15 Company Quick Takes: Boehringer takes out cancer vaccine company Amal; plus Farxiga setback, Alkermes and more

Boehringer buying cancer vaccine play Amal  Boehringer Ingelheim (Ingelheim, Germany) is acquiring Amal Therapeutics S.A. (Geneva, Switzerland), a University of Geneva spinout developing cancer vaccines. Amal's shareholders will receive an undisclosed upfront payment; the total...
Read More
01:58 , Jun 29, 2019 |  BioCentury  |  Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
Read More
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
Read More
17:12 , May 17, 2019 |  BC Extra  |  Financial News

Tools4Patient raises €4M to refine, expand placebo response analytics

As it seeks to apply its placebo response measurement tool to new therapeutic areas beyond pain, Tools4Patient has tapped investors for a €4 million ($4.5 million) series B round. The company's Placebell technology uses an...
Read More
21:28 , Apr 25, 2019 |  BC Extra  |  Company News

Alkermes sinks after reporting Aristada sales miss

Alkermes shares fell $4.44 (13%) to $30.31 Thursday after the company reported quarterly sales of schizophrenia therapy Aristada that fell short of both its own guidance and analysts' expectations. The company attributed the shortfall to...
Read More
22:34 , Apr 22, 2019 |  BC Extra  |  Company News

Management tracks: MeiraGTx, Retrophin, Aduro

MeiraGTx Holdings plc (NASDAQ:MGTX) said Katherine Breedis stepped down as CFO on April 16, a little over six months after she joined the gene therapy company. MeiraGTx said COO Richard Giroux will take on the...
Read More
19:10 , Apr 12, 2019 |  BioCentury  |  Product Development

Changing models and minds to improve access to addiction treatment

A lack of acknowledgment by key stakeholders in the healthcare system that medications can treat opioid abuse, along with a fragmented reimbursement system, means that effective treatments aren’t getting to the majority of patients who...
Read More
21:56 , Apr 10, 2019 |  BC Extra  |  Company News

U.S. fraud charges pummel Indivior shares

Indivior fell 75.90p (72%) to 30.05p on Wednesday after the U.S. Department of Justice indicted the company for allegedly defrauding providers and payers to increase prescriptions of its opioid dependence drug Suboxone sublingual film. Wednesday's...
Read More
20:38 , Apr 9, 2019 |  BC Extra  |  Company News

Management tracks: Cyclerion, Alkermes, Alder

A week after completing its spinout from Ironwood, Cyclerion has hired Andreas Busch as chief innovation officer. Busch was EVP, head of R&D and CSO at Shire plc and previously served as EVP, head of...
Read More
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
Read More